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A B S T R A C T
Chlorpyrifos (CPF) is a pesticide that causes tens of thousands of deaths per year worldwide. Chlorpyrifos
oxon (CPO) is the active metabolite of CPF that inhibits acetylcholinesterase. However, this presumed
metabolite has escaped detection in human samples by conventional methods (HPLC, GC-MS, LC-MS)
until now. A recently developed enzyme-based assay allowed the determination of CPO in the
nanomolar range andwas successfully employed to detect thismetabolite. CPO and CPFwere analysed in
consecutive plasma samples of 74 patients with intentional CPF poisoning. A wide concentration range
of CPO and CPF was observed and the ratio of CPO/CPF varied considerably between individuals and over
time. The ratio increased during the course of poisoning from amean of 0.005 in the ﬁrst few hours after
ingestion up to an apparent steady-state mean of 0.03 between 30 and 72 h. There was a hundred-fold
variation in the ratio between samples and the interquartile range (between individuals) indicated over
half the samples had a 5-fold or greater variation from the mean. The ratio was independent of the CPF
concentration and the pralidoxime regimen. CPO was present in sufﬁcient quantities to explain any
observed acetylcholinesterase inhibitory activity. The effectiveness of pralidoxime in reactivating the
inhibited acetylcholinesterase is strongly dependent on the CPO concentration. Differences in clinical
outcomes and the response to antidotes in patients with acute poisoning may occur due to inter-
individual variability in metabolism.
 2009 Elsevier Inc.
Contents lists available at ScienceDirect
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Chlorpyrifos (CPF) is one of the most commonly used
organophosphorus pesticides for domestic, agricultural and
industrial purposes. It may be estimated that it causes tens of
thousands of deaths per year worldwide [1,2]. CPF is a pro-poison
that requires metabolic activation to become a potent phosphor-
ylating agent, namely chlorpyrifos oxon (CPO) [3]. At low
concentrations, the desulfuration of CPF by human liver micro-
somes is due to the action of the polymorphically expressed
CYP2B6 owing to its favorable Vmax/Km ratio [4]. At high poison
concentration, however, an increasing proportion of CPF desul-Abbreviations: AChE, acetylcholinesterase (EC 3.1.1.7); BChE, butyrylcholinesterase
(EC 3.1.1.8); CPF, chlorpyrifos; CPO, chlorpyrifos oxon; PON 1, paraoxonase 1 (EC
3.1.8.1); RBC, red blood cells.
* Corresponding author. Tel.: +49 89 2180 75722; fax: +49 89 2180 75701.
E-mail address: peter.eyer@lrz.uni-muenchen.de (P. Eyer).
0006-2952  2009 Elsevier Inc.
doi:10.1016/j.bcp.2009.05.004
Open access under CC BY license.furation occurs due to the abundant CYP3A4 [5]. CPO is also rapidly
detoxiﬁed by human liver microsomes via CYP-dependent
deethylation and dearylation, and by glutathione-S-transferase
[6]. In addition, reactions with A-esterases such as paraoxonase 1
(PON 1; EC 3.1.8.1) or B-esterases such as carboxylesterase (EC
3.1.1.1) and butyrylcholinesterase (BChE; EC 3.1.1.8) in the liver
may rapidly degrade or scavenge CPO [7]. These polymorphisms in
the activating and detoxifying enzymes [8] are expected to lead to
wide inter-individual variability in exposure to CPO for a given CPF
load. However, further exploration of the importance of these
factors has been limited by the absence of a reliable method of
quantifying CPO in vivo.
Until recently [9], CPO had never been detected in the blood of
CPF-poisoned patients [10,11]. Yet we repeatedly observed that
plasma of CPF-poisoned patients was able to inhibit red blood cell
(RBC) acetylcholinesterase (AChE; EC 3.1.1.7) from healthy donors
in vitro. It had been noted that BChE had extremely high reaction
rates with CPO [12] and an enzyme-based assay was developed
using BChE (described in detail in [9]). In the current study, we




Serial blood samples stem frompatientswith acute chlorpyrifos
poisoningwhowere enrolled in two randomised controlled studies
(RCT1: ISRCTN02920054 and RCT2: ISRCTN55264358). The studies
were performed in Sri Lankan hospitals in Anuradhapura and
Polonnaruwa aimed at evaluating the efﬁcacy of oral super-
activated charcoal (RCT 1) or pralidoxime (RCT 2) in symptomatic
organophosphorus pesticide poisoning. Additional patients were
recruited in a prospective cohort study in Nuwara Eliya that was
assessing changes in neuromuscular junctional function in
organophosphorus pesticide poisoning. Ethics approval was
obtained from the Faculty of Medicine Ethics Committee of
Universities of Colombo and Peradeniya, and Oxfordshire Clinical
Research Ethics Committee. Written informed consent was taken
from each patient, or their relatives, in their own language. Study
details are reported elsewhere [2,13,14]. Treatment consisted of
ﬂuid resuscitation and atropine as described [15] and pralidoxime
chloride 1 g every 6 for 48 h (RCT1 and Nuwara Eliya cohort),
although there was no strict adherence to this regimen. Patients in
RCT2 were randomised to receive pralidoxime (2 g pralidoxime
chloride loading dose over 20 min, then 0.5 g/h until amaximumof
7 days) or an equal volume of normal saline in addition to the
supportive therapy mentioned above. The blood samples were
collected between 25 May 2004 and 18 October 2006.
Blood samples were collected into tubes containing EDTA prior
to pralidoxime, then at 1, 4, 12, and 24 h after administration, then
once daily until discharge or death. A 0.2 mL blood sample was
diluted at the bedside immediately after collection with 4 mL of
ice-cold saline and frozen to 23 8C until analysis of AChE activity.
The remaining sample was promptly centrifuged and the aspirated
plasma frozen at 23 8C until analysis of BChE activity, inhibitory
activity, and the concentration of CPF and CPO [15].
2.2. Analyses
Laboratory analyses were conducted in Munich, Germany.
AChE activity was determined in native RBCs (AChE in vivo) and
after reactivation with supra-therapeutic obidoxime (AChE in
vitro) to estimate the reactivatable fraction. These assays were
performed using a modiﬁed Ellman assay as described [16]. BChE
activity [15] and inhibitory activity of plasma [17] were assessed
as reported. In short, inhibitory activity of patient plasma was
tested by incubating 3 volumes of hemolysate (3 g Hb/100 mL
0.1 M phosphate buffer, pH 7.4; washed red blood cells from a
healthy donor) with 1 volume of patient plasma at 37 8C for
60 min.
CPF was determined by reversed phase HPLC with detection at
288 nm. Speciﬁcally, 0.5 mL plasma was mixed with 10 mL of
500 mM fenitrothion as internal standard to control the extraction
yield. The plasma was extracted twice with 1 mL n-hexane for
1 min and residual lipoproteins in the combined hexane phases
were precipitated with 50 mL 1 M perchloric acid, followed by
centrifugation (10.000 rpm for 1 min). The hexane phase was
transferred in a borosilica vial and 10 mL of DMSO was added as
keeper. Hexane was evaporated at approximately 40 8C for 30 min
in a Speed-Vac-Concentrator. The residuewas dissolved in 90 mL of
methanol:water (70/30, v/v) and 50 mL were applied to LiChro-
sphere 100 RP-18, 5 mm, 125 mm  4 mm (E. Merck, Darmstadt,
Germany) and eluted at a ﬂow rate of 1 mL/min by gradient
elution. The mobile phase started with 65% methanol in water andwas linearly increased to 77% methanol between 4.5 and 7.5 min.
Typically, fenitrothion was eluted after 3.3 min and chlorpyrifos
after 11.5 min. The lower limit of quantiﬁcation (LOQ) was 0.1 mM
in plasma.
CPO was determined by an enzyme-based assay as described
recently [9]. In short, CPO was extracted with n-pentane and the
reconstituted residue titrated with puriﬁed horse BChE, allowing
an LOQ of 0.5 nM. The data were corrected for 83% recovery of CPO
from plasma [9].
Horse BChE (Cat. No C-1057) and CPF Pestanal1 were from
Riedel-de Haen, Sigma, Taufkirchen, Germany; CPOwas a generous
gift from DowAgroSciences, Indianapolis, IN. Both compounds had
purities 99%. Fenitrothion (95.5% pure) was obtained from Dr.
Ehrenstorfer, Augsburg, Germany. All other reagents were from
commercial sources at the purest grade available.
Pralidoxime was determined by HPLC on reversed phase
material with an ion-pairing reagent. Speciﬁcally, 100 mL plasma
was mixed with 30 mL trichloroacetic acid (1 M) and spun down.
Eighty microliter of supernatant was mixed with 40 mL of n-
heptanesulfonate reagent (PIC B7 lowUV,Millipore) and 30mL of a
sodium formate buffer (1 M, pH 3.5) to give a ﬁnal pH  3.0. Fifty
microliter was applied to a Purosphere Star RP-18 column
(55 mm  4 mm, 3 mm, Merck) and eluted with a linear methanol
gradient (0–15%within 7.5 min) in 5 mMPIC-B7 low UV reagent in
water at a ﬂow rate of 1.4 mL/min (20–25 8C) and detection at
293 nm. Typically, pralidoxime was eluted after 5.6 min. LOQ was
1mM pralidoxime in plasma.
Free EDTA in plasma samples was titrated with a standard
calcium chloride solution (50 mM) in the presence of the calcium
indicator eriochrome black T (CAS 1787-61-7; 10 mg eriochrome
black + 1 g sodium chloride triturated and dissolved in 2.5 mL
water). Speciﬁcally, 50 mL plasma was diluted with 450 mL
distilled water, 5mL sodium hydroxide (2 M) and 1mL indicator
solution added and titrated with calcium chloride until formation
of a pink coloration.
2.3. Calculations
Data were included when CPF was ingested (on the basis of
history and/or analytical data) with no other organophosphorus
compound being detected, BChE was mostly inhibited (typical for
CPO) and AChE not signiﬁcantly aged (typical for a diethylpho-
sphorylated enzyme). Data were excluded when CPF and/or CPO
were below the LOQs or when the time of ingestion or blood
sampling was ambiguous. Data were also excluded when plasma
pralidoxime was higher than 0.5 mM, indicating that blood was
withdrawn proximally from the infusion site. In these cases
signiﬁcant post-sampling reactions had to be suspected.
The relationship between measured and calculated (predicted)
CPO concentrations was determined using equations as deduced
elsewhere [18]. This approach has been validated for paraoxon





ki  ½P  ð1þ KD=½OxÞ
E = active enzyme; EP = phosphorylated, but unaged enzyme;
EPOx = complex of oxime and phosphorylated, but unaged
enzyme; [EP + EPOx] is the reactivatable enzyme = AChE in
vitro–AChE in vivo; kr is the ﬁrst-order reactivation rate constant;
KD is the dissociation constant of the complex EPOx; ki is the
second-order inhibition rate constant; [P] is the oxon concentra-
tion; [Ox] is the oxime concentration.
The constants for reactivation of human diethylphosphoryl-
AChE by pralidoxime are known from in vitro experiments using
human red blood cells [18,19], [E], [EP + EPOx] and [Ox] were
Table 1
Plasma concentrations of CPF and CPO after various time intervals post poisoning.
Time interval (h) CPF (mM) CPO (nM) CPO/CPF  1000 n
0–4 2.54 (1.6–4.7) 10.1 (4.5–22.2) 4.2 (1.9–9.5) 52
4–8 1.65 (0.7–3.2) 11.9 (6.5–21.5) 6.8 (4.3–14.0) 67
8–16 0.70 (0.4–1.2) 12.7 (5.5–22.5) 17.5 (9.2–31.6) 59
16–24 0.44 (0.3–1.5) 9.6 (4.1–30.1) 14.2 (10.5–42.6) 30
24–36 0.47 (0.3–1.1) 14.1 (4.7–34.5) 28.6 (11.3–44.4) 45
36–60 0.66 (0.2–1.0) 16.7 (3.4–68.4) 29.2 (14.4–70.7) 41
60–84 0.46 (0.2–0.8) 22.7 (2.2–59.9) 37.3 (12.7–65.3) 27
84–120 0.39 (0.2–0.7) 7.1 (4.2–40.2) 25.0 (15.4–53.6) 28
Plasma samples (n = 357) of 72 patients were eligible (CPF and CPO > LOQ). The
ratio CPO/CPF was calculated from the individual sample values. Data are median
values along with the interquartile range in brackets.
Fig. 2. Ratio of CPO/CPF vs. time post-ingestion of CPF. Data are median values with
their IQRs of 72 eligible patients from Table 1. For illustration a mono-exponential
association function was ﬁtted to the median values.
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1;
KD = 330 mM and ki = 6  106 M1 min1 [18].
The fraction of active test AChE upon incubation with known
amounts of CPO in plasma samples was calculated discretely in 1-
min increments using the following equation:
E ¼ E0  ki  ðE EPÞ  0:15 ðCPO0  EPÞ;
with E0 and CPO0 being the AChE and total CPO concentration at
t = 0 (the factor 0.15 corrects for the fraction not bound reversibly
to albumin).
Calculations were done with Microsoft Excel 2004. Correlation
analyses, Mann–Whitney U test and graphical presentations were
performed with Prism4, GraphPad, San Diego, CA.
3. Results
3.1. Time course of CPO formation
Formation of CPO occurred quite early after CPF ingestion. In
one patient we detected signiﬁcant amounts of CPO 70 min after
CPF ingestion with BChE and AChE depressed to less than 2% and
10% of normal, respectively. Fig. 1 shows the time course of plasma
CPF and CPO in a patient who was admitted some 5 h post-
ingestion and received no pralidoxime. Here, maximal CPO
concentration appeared after a delay of several hours. As expected,
the ratio of CPO/CPF increased with time, starting with less than
0.005 in the period between 0 and 4 h after ingestion and
approaching 0.03 on average in the period between 24 and 120 h.
Table 1 shows the median plasma concentrations along with the
interquartile ranges of CPF and CPO in 72 eligible patients (with
and without pralidoxime treatment, no signiﬁcant difference),
where sufﬁcient data were available to determine the CPO/CPF
ratio at various time intervals post-ingestion. Fig. 2 shows the time
course of the ratio of CPO/CPF and a mono-exponential association
curve that was ﬁtted to the median values, without implying a
speciﬁc mechanism.
The variation of the ratio CPO/CPF was large, and some
individuals showed a ratio below 0.01, while others had >0.05
in the period between 24 and 120 h, when a steady-state was
reached (cf. Fig. 2). The ratio CPO/CPF showed no dependence on
the CPF concentration. When plotting the ratio CPO/CPF in a
logarithmic scale vs. the CPF concentration (Fig. 3), the linear
regression showed no signiﬁcant deviation of the slope from zero
(p > 0.4; not shown). These datawere indicative that in this setting
CPO formation and decomposition did not showa saturation (dose-
limiting) phenomenon.Fig. 1. Time course of CPF and CPO concentrations in a patient with CPF self-
poisoning.
The patient did not receive pralidoxime. X-axis shows the time post-ingestion. Note
the different concentration scales.
Fig. 3. Ratio of CPO/CPF vs. CPF concentration in patient samples 24–120 h post-
ingestion from the dataset shown in Fig. 2. Linear regression analysis of the
logarithmically transformed ratio vs. CPF concentration gave a slope not
signiﬁcantly different from zero.3.2. Dependence of AChE-inhibitory material in plasma on CPO
concentration
A large scattering of data was observed in the ratio of AChE-
inhibitory activity of patients’ plasma and the CPO concentration,
whether or not patients had received pralidoxime. As expected, the
inhibitory activity was on average higher in the group who did not
receive pralidoxime. Fig. 4 shows the scatter of data from patients
who were not administered pralidoxime (absence conﬁrmed by
HPLC). A hyperbola ﬁtted by non-linear regression is shown (full
Fig. 4. Inhibitory activity of patient’s plasma towards RBC–AChE and its dependence
on the measured concentration of CPO.
Plasma samples (n = 241 of 67 patients), where pralidoxime was negative, were
incubatedwith 3 volumes of haemolysate of an unexposed donor for 60 min and the
degree of AChE inhibition determined. For illustration a rectangular hyperbola was
ﬁtted to the data points (solid line). Using the inhibition rate constant of human red
blood cell AChE allowed the calculation of the expected curve (dotted line).
F. Eyer et al. / Biochemical Pharmacology 78 (2009) 531–537534line). The normal concentration of AChE in whole blood is about
15 nM [20,21], hence the concentration of AChE in the inhibition
assay was about 11.3 nM. Using the inhibition rate constant of
6  106 M1 min1 [18] allows a rough estimate of the inhibition
progress, which was essentially complete after the 60 min
incubation time. As shown in Fig. 4, in most cases AChE was
inhibited to a less extent than predicted from the CPO concentra-
tion (dotted line). The ratio of inhibitory activity found/predicted
in samples with and without PAM did not depend on the CPO
concentration as shown in the semilogarithmic plot of Fig. 5. Linear
regression analysis of the data indicated that the slopes were not
signiﬁcantly different from zero (p >0.2 and >0.5, respectively).
These results pointed to competing side reactions of CPO during
the incubation period.
Since BChE was essentially completely inhibited at even low
concentrations of CPO we suspected that OP-hydrolases were
degrading CPO in the inhibition assay. PON 1 is notorious for its
high activity towards CPO [22]. This enzyme, however, requires
free calcium ions, both for stability and activity [23]. Hence, this
enzyme should be inactivated in EDTA-based plasma samples.
We measured the free concentration of EDTA and found in 487
out of 490 plasma samples that excess EDTA was higher than
0.5 mM (median 4 mM). This should be sufﬁcient to completelyFig. 5. Semilogarithmic plot of the ratio of found and expected inhibitory activity of
plasma from CPF-poisoned patients vs. the total CPO concentration. Closed circles
and full line from pralidoxime-free samples; Xes and broken line samples
containing pralidoxime between 13 and 150mM.inactivate PON 1 and this implies other mechanisms of CPO
inactivation/sequestration may exist.
3.3. Inﬂuence of CPO and pralidoxime concentrations on AChE activity
Fig. 6 shows the effects of CPO and pralidoxime plasma
concentrations on the percentage of active AChE in two selected
patients with a similar time course of the CPF concentrations.
Patient A received pralidoxime by the continuous infusion
regimen while patient B received the intermittent lower dose
scheme. In both cases, AChE activity was largely inhibited before
pralidoxime. In case A, AChE reactivation was sustained and
approached some 90% when pralidoxime was given for 5 days. In
contrast, intermittent doses of pralidoxime for less than 48 h
resulted in gradual re-inhibition of reactivated AChE, particularly
since CPO concentrations were much higher than in patient A.
The mutual dependence of the RBC–AChE activity on the
pralidoxime and the CPO concentration was analysed according to
the equation given in the Section 2. Forty-four patients who
received pralidoxime, were eligible for the analysis contrasting the
CPO concentration predicted from the RBC–AChE activity with the
measured CPO.We excluded all data where CPOwas below 0.5 nM
(LOQ), pralidoxime given less than 1 h before sampling and where
the pralidoxime concentration was below 13 mM. At this
concentration the half-life for reactivation is approximately 1 h
[19] and steady-state conditions could not be expected at lower
concentrations. The expected free CPO concentration could be
calculated from the ratio of inhibited, but reactivatable enzyme
and the active enzyme, i.e. [EP + EPOx]/[E]. In doing so, we
observed a large scattering of the ratio of CPO found/CPOpredicted.
Fig. 7 shows a plot of data (from 20 subjects with at least 3 samples
that met the above criteria). The ratio of CPO found vs. CPO
predicted is given in a logarithmic scale (median, IQR). The
predicted CPO concentration is the free (active) fraction. Thus we
expected a mean ratio of about 6 (dashed line), corresponding to
85% reversible albumin binding [7] as CPO from plasma was
extracted by an organic solvent determining both the bound and
free fractions of CPO.
4. Discussion
Since CPO reacts more than 2 orders of magnitude faster with
BChE than with AChE [12], CPF-poisoned patients usually arrive at
hospital with completely inhibited BChE while RBC–AChE is often
less affected. These sequestering reactions along with the effective
hydrolysis brought about by PON 1 were thought to keep the CPO
steady-state concentration in blood too low for conventional
determination (HPLC, GC-MS, LC-MS) [7,11]. However, in previous
studies in CPF-poisoned patients [2] we observed that the patient’s
plasma was able to inhibit AChE of added test erythrocytes. The
consistent presence of ‘‘inhibitory activity’’ of plasma led us to
develop the enzyme-based assay for CPO.
Using the standard assay for CPO determination [9], reliable
results were obtained in the concentration range of 2–20 nM CPO
in plasma (accuracy  10%, reproducibility  4% (95% CI)). When it
turned out that BChE was almost completely inhibited, plasma was
diluted 1:10 or more with buffer to arrive at the useful range. Of
course, the biological assay lacks speciﬁcity since all highly reactive
inhibitors that are extracted with n-pentane may mimic CPO. With
the exception of the nerve agents soman and cyclosarin no oxons are
so reactive as CPO in inhibiting BChE [12,24,25]. Of the insecticidal
organophosphates diazoxon is next reactive, but still 20-times less
than CPO [24].We intentionallyminimized the reaction time for BChE
inhibition to largely exclude the effect of potential cross-reacting
oxons. Signiﬁcant CPF concentrations were veriﬁed in all patients
included and the presence of the lipophilic organophosphates
Fig. 6. Inﬂuence of CPO and pralidoxime concentrations on AChE activity. Two patients, A and B, with a similar time course of plasma CPF had very different CPO
concentrations in their plasma. Patient A received the intensiﬁed pralidoxime regimen with continuous infusion for>4 days; patient B received the intermittent bolus doses
for <2 days, resulting in the re-inhibition of reactivated AChE. % AChE refers to the fraction of active enzyme from the pool of reactivatable AChE, thus ignoring the aged
fraction.
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presence of major concentrations of dimethylphosphoryl compounds
could be ruled out because erythrocyte AChE did not indicate the
rapid ageing seen with these compounds [15]. Earlier studies in Sri
Lanka have shown that the alleged poison was conﬁrmed in more
than 90% of the patients [2]. Hence, we are conﬁdent that our assay
detected in fact CPO and no other BChE inhibitors.
The present study conﬁrms that CPO is present in more than
sufﬁcient quantities to be responsible for all the ‘‘inhibitory
activity’’ of the plasma of CPF-poisoned patients. It also casts doubtFig. 7. Ratio of found and expected CPO concentrations in 20 patients who were
treated with pralidoxime. CPOwas calculated from the ratio of active and inhibited,
but reactivatable AChE, the measured pralidoxime concentration and the known
kinetic constants as indicated in the Section 2. Data are given as median values
(n  3; IQR) of 20 eligible patients during the expected steady-state of AChE
inhibition and reactivation. Note the semilogarithmic scale. The dotted line
intersecting the Y-axis at 6 corresponds to 85% reversible albumin binding of CPO in
plasma, which is pharmacodynamically inactive, but was determined by solvent
extraction.on the accuracy of non-speciﬁc bioassays such as the ex vivo
‘‘inhibitory activity’’ and suggests that they may signiﬁcantly and
variably under-estimate the true extent of in vivo AChE inhibitory
activity. As shown in Fig. 4 the correlation of CPOwith inhibition of
test AChE was not as strong as anticipated. Even if we assume that
some 85% of CPO is bound to albumin [9], we would expect
somewhat slower but ﬁnally complete inhibition of AChE if the
molar concentration of CPO exceeded that of AChE (11.3 nM). This
expectation was usually not met (Figs. 4 and 5), so it appears likely
that CPO was subject to competing reactions ex vivo. Hydrolysis of
CPO by PON 1 in the inhibition assay can be ruled out since EDTA in
the plasma samples leads to complete inactivation of PON 1 [26].
Albumin, however, not only binds CPO reversibly, but also
hydrolyses CPO as demonstrated by the liberation of 3,5,6-
trichloropyridinol in the absence of free calcium ions [27]. This
reﬂects the covalent binding of CPO to tyrosine 411 in human
albumin [28]. Based on the assumption of an albumin concentra-
tion in human plasma of about 4 g/100 mL, our inhibition assay
contained 1% albumin. It is known that bovine serum albumin
‘hydrolyses’ CPO at Vmax of 0.9 nmol/min/mg protein with a Km
value of 0.4 mM at pH 7.4 and 37 8C [27]. Given that human serum
albumin has similar kinetic constants, we can deduce that 20 nM
CPO will be inactivated at a rate of 0.45 nM/min. This may be
compared with the more rapid inhibition rate of 1.35 nM/min
(11.3 nMAChE, 20 nMCPO, ki = 6  106 M1 min1, see above). It is
clear that the (initial) inhibition rate will be slowed down upon
gradual inhibition of AChE, while covalent binding to albumin that
has a large molar excess of about 150mM still proceeds. This latter
pseudo-ﬁrst-order reaction explains the observation that the
consumption of CPO was largely independent of the CPO
concentration (Fig. 5). If other plasma proteins were also involved
in CPO binding the effect of competing reactions might be even
greater. In fact, data exist showing that mouse plasma contains at
least 11 proteins capable of binding organophosphorus com-
pounds under physiological conditions [29].
F. Eyer et al. / Biochemical Pharmacology 78 (2009) 531–537536The inﬂuence of pralidoxime on the inhibitory activity of the
patient’s plasma (Fig. 5) was only evident at low CPO concentra-
tions, because the bioreactor AChE + pralidoxime has only a
limited capacity to degrade CPO, due to the low molar AChE
concentration present. The large scattering of the data at low-to-
intermediate CPO concentrations (up to 100 nM CPO) in the
presence of pralidoxime may be mainly caused by variations of its
concentration in the plasma samples. Taken together in the
absence of pralidoxime, roughly 2/3 of CPO in EDTA-based plasma
was capable of inhibiting AChE, the remainder had most probably
reacted covalently with other proteins with albumin being the
most favorite candidate.
Appearance of CPO in plasma lags behind CPF. This may be due
to delayed formation or, more probably, due to sequestering
reactions with limited capacity. CPO is rapidly bound to B-
esterases, such as BChE, AChE and carboxylesterase. The latter
enzyme has a high binding capacity, which in the rat was
estimated to be 3 orders in magnitude higher than that of BChE
[11]. Circulating carboxylesterase is not found in human plasma
[30], but located in tissues. When these B-esterases are saturated,
free CPO may escape the major site of production, the liver.
Concomitantly, CPO is prone to degradation by A-esterases (true
hydrolysis) and by CYP450-mediated inactivation [11]. PON 1 has
favorable kinetic properties towards CPO hydrolysis, but shows a
polymorphism that affects differently the catalytic efﬁciency of
organophosphates. Thus, PON 1 192R is superior in hydrolyzing CPO
and provides better protection against CPO exposure in PON 1 null
mice than PON 1 192Q [31]. Interethnic variability of the genetic
makeup is remarkable in that PON 1 RRwas rarely found in Indians
(3%) but often in Chinese (32%), while the inverse relationship was
found with the PON 1 QQ genotype [32]. In addition, a large
variation in enzyme levels is found among individuals even with
the same genotype [22]. Hence, steady-state concentrations of CPO
(at constant CPF) are expected to varywidely.We observed steady-
state ratios of CPO/CPF after some 30 h post-ingestion with a
spread of the interquartile range of about 5 (cf. Fig. 2). The ratiowas
not dependent on the CPF concentration, indicating that the
equilibrium of CPO formation and degradation did not show
saturation phenomena. Desulfuration of CPF by human hepatic
CYPs is mainly brought about by CYP2B6 and CYP3A4 with Km
values of about 1 and 30 mM, respectively, at comparable Vmax
values. Since the former CYP is prone to polymorphism in protein
expression [33,34], large variability in oxon formation can be
expected [4]. In fact, a variability of CPO/CPF of more than 1 order
in magnitude was observed (Fig. 5).
Pralidoxime was able to reactivate inhibited RBC–AChE in CPF-
poisoned patients as shown in Fig. 6. Its effectiveness depended
both on its plasma concentration and on the CPO concentration.
The two examples shown indicate that the variability in CPO
production and also that if pralidoxime is ceased while there is
measureable CPO present then the RBC–AChE will not remain
reactivated. Such considerations are likely to apply to all OP,
particularly when highly lipophilic agents are involved [2,15]. As
deduced recently [18], the theoretical plasma concentration of CPO
should be able to be calculated from the ratio of inhibited vs. active
AChE, the plasma concentration of the oxime and the kinetic
constants of the reactions involved (see Section 2). However, we
observed a very large variation in the found/predicted CPO
concentration ratio. We expected a mean ratio of about 6 (dashed
line), corresponding to 85% reversible albumin binding [9] as CPO
from plasmawas extracted by an organic solvent determining both
the bound and free fractions of CPO and the prediction only
estimates free CPO. This variation seems much greater than
variability in protein binding can explain but further studies are
required to determine why the clinical samples show this
discrepancy.In conclusion, this newly developed CPO assay gives reliable
results that enable a better assessment of the mechanisms behind
inter-individual variation in susceptibility in CPF poisoning. The
study has shown that the steady-state ratios of CPO/CPF vary
widely and probably mirror the activating and detoxifying
capabilities. Thus, a large variation in the susceptibility for CPF-
and CPO-mediated toxicities has to be taken into account when
debating safety margins of CPF.
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